Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Effect of Carbohydrate Loading 2 Hours Before Gastroscopy on Gastric Residual Volume and Patient's Well-being Score (Carborie)

5 novembre 2021 aggiornato da: MOHD FIRDAUS BIN ZULKIFLI, Hospital Universiti Sains Malaysia

The Effect of Carbohydrate Loading 2 Hours Before Upper Endoscopy on Gastric Residual Volume and Patient's Well-being Score : A Single-Blind, Randomized Controlled Trial Study

This is a single-blind randomized controlled trial with a stratified (diabetes mellitus, non-diabetes mellitus), balanced randomization (1:1), placebo-controlled study regarding the effect of carbohydrate loading 2 hours prior to the outpatient upper endoscopic procedure. All patients who were assigned for outpatient oesophagogastroduodenoscopy (OGDS) were invited to join in this study voluntarily from January 2021 until August 2021. This study was conducted in the Endoscopy Unit, Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia. The endoscopists that performed this procedure were blinded and there was trained staff who was not involved in the study to assess the well-being score. The study protocol had been approved by the Human Research Ethics Committee of Universiti Sains Malaysia (JEPeM) with the assigned protocol code USM/JEPeM/20080414.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Patient planned for OGDS in HUSM will be randomized into 2 groups. Plain water is given to group A of subject and carbohydrate loading is given to group B subject 2 hours before OGDS. Gastric residual volume is visualized directly and measured through aspiration via OGDS and subject's well-being is assessed for both group of the subject prior and after clear fluid have been given.

Methodology :

Research design :- This is a single-blind randomized controlled trial. This is a stratified (diabetes mellitus, non-diabetes mellitus) with balanced randomization (1:1), placebo-controlled study Study area :- This study will be conducted in the endoscopy room, Hospital Universiti Sains Malaysia (HUSM) in Kubang Kerian, Kelantan, Malaysia

All subjected planned for OGDS with the complaint of one or more of the following symptoms : Bothersome postprandial fullness, early satiety, epigastric pain or epigastric burning and fulfill the inclusion criteria are selected. Patients will be approached and be explained regarding the study in surgical outpatient clinic before OGDS. The patient will be approached again on the day of OGDS, if agree to participate, informed consent will be obtained. Informed consent will be obtained after explanation regarding the study and procedure again by researcher nurse.

The allocation sequence is according to computer-generated random number list, it was prepared by an investigator with no clinical involvement in the trial. The allocation sequence was concealed from researcher enrolling and assessing participants. The allocation sequence will be sealed in sequentially numbered and opaque envelopes. A manila card will be placed inside envelop to render it impermeable to intense light. To prevent subversion of the allocation sequence, the name and identification number of the participants will be written on a book together with the series number on the envelope. The details in the book will be kept confidentially.

After enrolled subject complete all the baseline assessment, the corresponding envelope will be enclosed by the trained staff (who not involved in the study) who prepare the drink. The staff need to ensure that the envelop is still sealed when receiving it. The staff will prepare the drink into an identical container according to the assignment.

The subjects are randomized into 2 groups: 1 group with 400mL plain water and another group given 1 packet carborie (400mL). Subjects need to finish the drink over 10 minutes. After that, subjects are not allowed to leave endoscope room until finish OGDS to prevent consumption of other drink or food.

2 hours after that, the subject undergoes OGDS. OGDS is performed following the standard protocol.

  1. The patient lies in the left lateral position
  2. Medication/lignocaine spray to numb the back of throats (spray) will be given to prevent gagging during the passage of the instrument
  3. A plastic mouth guard (mouthpiece) is placed between the teeth to prevent damage to the teeth and endoscope
  4. The endoscope (also called a gastroscope) will be inserted through the mouthpiece
  5. A small container or yankauer suction is placed close to the mouth of a patient to collect saliva during and after the oesophagogastroduodenoscopy (OGDS)
  6. The endoscope will be inserted along the middle line of the soft palate
  7. Once endoscope advanced, the patient may be asked to swallow to facilitate advancement of scope
  8. Throughout the procedure, no water flushing is allowed, only air inflation is allowed.

Visualized pooling of fluid in the stomach is aspirated until dry via direct visualization with the endoscope. The aspirated fluid will be collected in the suction reservoir and the fluid will be measured

Subject's well-being score is assessed via visual analogue scale (VAS) which consist of 5 parameters: hunger, thirst, anxiety, tiredness and general discomfort. This scale will be used repeatedly during this study to assess the patient's well-being. The trained staff nurse will ask the patient regarding the level of 5 parameters and subject need to mark [X] somewhere along the horizontal line given before drink and before OGDS procedure.

All subjects are advised to inform assessor if there is an adverse reaction. Medical personnel are available to manage any adverse events that might occur throughout the procedure.

The possible risk that may arise in the study includes injury to the gastrointestinal wall, aspiration and bleeding which is the similar risk for all patient undergoing for OGDS procedure. The small volume of the drink will not cause psychological distress to the subject, but its taste may not be palatable.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

78

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Kelantan
      • Kota Bharu, Kelantan, Malaysia, 15200
        • Department of General Surgery

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patient 18 years old and above
  • Agree to participate

Exclusion Criteria:

  • History of upper gastrointestinal surgery
  • Patient with active gastrointestinal bleeding
  • Unstable clinical condition
  • Mentally disable or who cannot give an informed consent
  • Patient on the nasogastric feeding tube
  • Pregnant patient
  • American Society of Anesthesiologists classification of physical status grade 3 or above
  • Insulin dependent Diabetes Mellitus more than 10 years
  • Patient who is carbohydrate intolerance

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Plain water
Group A patient will be given 400cc of plain water, 2 hours prior to gastroscopy
Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
Sperimentale: Carborie
Group B patient will be given 400cc of carborie (carbohydrate drink), 2 hours prior to gastroscopy
carbohydrate drink

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To compare the gastric residual volume 2 hours after carbohydrate loading (intervention group) and plain water group (control group)
Lasso di tempo: 2 hour before OGDS
Patients will be randomised into control group and intervention group. Those in intervention group will have to drink clear water containing carbohydrate (carborie) 2 hours prior to gastroscopy. Endoscopist will measure patient's gastric residual volume. Residual gastric fluid will be aspirated into the container, final volume will be measured.
2 hour before OGDS

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To compare the patient's well-being after ingestion of carbohydrate loading (intervention group) and plain water (control group)
Lasso di tempo: 2 hours
To assess patient well-being score before and after giving carborie load. Visual analogue scale (VAS) used for assessment of patient well-being. Just before and after the ingestion of the clear fluid patients are told to indicate the level of discomfort on a visual analogue scale which ranged from 0mm to 100mm. Zero signifying not at all while 100 signify the most imaginable/maximum discomfort.
2 hours

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To assess the effect of carbohydrate loading in patient planned for OGDS in HUSM
Lasso di tempo: 2 hours prior OGDS
To assess gastric residual volume 2 hour prior OGDS
2 hours prior OGDS

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Nizam Hashim, Master, HUSM, Kubang Kerian, Malaysia

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2021

Completamento primario (Effettivo)

31 agosto 2021

Completamento dello studio (Effettivo)

20 ottobre 2021

Date di iscrizione allo studio

Primo inviato

9 ottobre 2021

Primo inviato che soddisfa i criteri di controllo qualità

3 novembre 2021

Primo Inserito (Effettivo)

4 novembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2021

Ultimo verificato

1 novembre 2021

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • HUSM Malaysia

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Volume residuo gastrico

Prove cliniche su Plain water

Sottoscrivi